TISA 818
Alternative Names: TISA-818Latest Information Update: 06 Nov 2025
At a glance
- Originator EnliTISA (Shanghai) Pharmaceutical
- Developer EnliTISA Shanghai Pharmaceutical
- Class Anti-inflammatories; Antifibrotics
- Mechanism of Action Antioxidants
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Adult respiratory distress syndrome
- Phase I/II Stomatitis
- Phase I Idiopathic pulmonary fibrosis
Most Recent Events
- 04 Sep 2025 EnliTISA Shanghai Pharmaceutical plans to file a regulatory application in Chronic obstructive pulmonary disease for clinical trial approval (Enlitisa (Shanghai) Pharmaceutical pipeline, September 2025)
- 05 Sep 2024 Preclinical trials in Stomatitis in China (Topical) before September 2024 ((Enlitisa (Shanghai) Pharmaceutical pipeline, September 2025)
- 27 Nov 2023 National Medical Products Administration approves CTA for clinical trial in Idiopathic pulmonary fibrosis